Stereotactic radiotherapy versus surgery for early-stage operable lung cancer: More questions than answers

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 10, 2015, Pages 1293-1295

  Verma, Vivek ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RECURRENCE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG SURGERY; NOTE; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; RECURRENCE FREE SURVIVAL; STEREOTACTIC BODY RADIATION THERAPY; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; PATHOLOGY; RADIOSURGERY;

DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RADIOSURGERY;

EID: 84944741177     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0155     Document Type: Note

References (21)

1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
2. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2010;140:377-386.
3. Grills IS, Mangona VS, Welsh R, et al. Outcomes of stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-935.
4. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670.
5. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 2004;101:1623-1631.
6. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-100.
7. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011;81:1352-1358.
8. Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable stage I non-small-cell lung cancer: a Markov model-based decision analysis. Int J Radiat Oncol Biol Phys 2011;81:964-973.
9. Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 2013;24:1543-1548.
10. Mokhles S, Verstegen NE, Maat AP, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 2015;87:283-289.
11. Timmerman RD, Paulus R, Pass HI, et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 7523.
12. Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan clinical oncology group (JCOG0403). Int J Radiat Oncol Biol Phys 2010;78:S27-28.
13. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015;16:630-637.
14. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012;13:802-809.
15. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:348-353.
16. Verma V. Lung cancer: implementing lung-cancer screening-oncological 'grey areas'. Nat Rev Clin Oncol 2015;12:256-257.
17. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012;102:335-342.
18. Mattonen SA, Palma DA, Haasbeek CJ, et al. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. Acta Oncol 2013;52:910-918.
19. Palma D, Visser O, Lagerwaard FJ, et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011;101:240-244.
20. Louie AV, Senan S, Patel P, et al. When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer? A decision analysis. Chest 2014;146:1021-1028.
21. Cao C, Chandrakumar D, Gupta S, et al. Could less be more? A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer 2015;89:121-132.